See more : Etihad Atheeb Telecommunication Company (7040.SR) Income Statement Analysis – Financial Results
Complete financial analysis of ProQR Therapeutics N.V. (PRQR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProQR Therapeutics N.V., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MiCo Ltd. (059090.KQ) Income Statement Analysis – Financial Results
- Safe-T Group Ltd. (SFET) Income Statement Analysis – Financial Results
- MagIndustries Corp. (MAAFF) Income Statement Analysis – Financial Results
- CyrusOne Inc. (CONE) Income Statement Analysis – Financial Results
- COLUMBIA WORKS INC (146A.T) Income Statement Analysis – Financial Results
ProQR Therapeutics N.V. (PRQR)
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 4.04M | 1.35M | 0.00 | 1.93M | 4.94M | -1.53M | 2.28M | 9.41M | 313.00K | 0.00 |
| Cost of Revenue | 133.52K | 2.48M | 0.00 | 2.19M | 116.82M | 983.51K | 1.00M | 1.28M | 482.85K | 0.00 | 0.00 |
| Gross Profit | 6.38M | 1.56M | 1.35M | -2.19M | -114.89M | 3.96M | -2.53M | 1.00M | 8.92M | 313.00K | 0.00 |
| Gross Profit Ratio | 97.95% | 38.68% | 100.00% | 0.00% | -5,943.61% | 80.09% | 165.49% | 43.84% | 94.87% | 100.00% | 0.00% |
| Research & Development | 25.15M | 50.87M | 42.22M | 38.14M | 46.49M | 29.51M | 31.15M | 31.92M | 23.40M | 10.27M | 2.57M |
| General & Administrative | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Other Expenses | -3.01M | -765.00K | -1.04M | 9.37M | 1.93M | 5.76M | 1.50M | 1.83M | 3.24M | 313.00K | 0.00 |
| Operating Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Cost & Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Interest Income | 2.59M | 106.00K | 5.00K | 313.00K | 402.00K | -792.00K | -3.18M | 470.00K | 6.17M | 4.33M | 24.00K |
| Interest Expense | 1.20M | 5.13M | 3.41M | 2.04M | 1.08M | 810.00K | 596.00K | 538.00K | 395.00K | 265.00K | 38.00K |
| Depreciation & Amortization | 2.51M | 2.48M | 2.42M | 2.19M | 2.05M | 983.51K | 1.00M | 1.28M | 480.00K | 126.00K | 24.00K |
| EBITDA | -24.10M | -56.46M | -54.95M | -136.56M | -174.27M | -35.29M | 0.00 | -120.55M | -84.24M | -49.70M | -3.19M |
| EBITDA Ratio | -369.93% | -1,470.99% | -4,089.81% | 0.00% | -2,965.65% | -831.05% | 2,676.78% | -1,759.68% | -316.34% | -5,318.85% | 0.00% |
| Operating Income | -31.86M | -64.72M | -57.19M | -42.37M | -57.45M | -36.29M | -40.50M | -39.57M | -27.00M | -16.46M | -3.24M |
| Operating Income Ratio | -489.09% | -1,603.07% | -4,223.86% | 0.00% | -2,971.81% | -734.53% | 2,648.66% | -1,734.14% | -287.05% | -5,259.11% | 0.00% |
| Total Other Income/Expenses | 4.05M | 1.05M | -3.47M | -4.12M | 117.65M | -792.00K | 850.31K | 470.00K | 6.17M | 4.33M | -14.00K |
| Income Before Tax | -27.81M | -64.80M | -61.56M | -46.49M | -56.61M | -37.09M | -43.67M | -39.10M | -20.83M | -12.13M | -3.25M |
| Income Before Tax Ratio | -426.97% | -1,605.03% | -4,546.75% | 0.00% | -2,928.82% | -750.56% | 2,856.31% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| Income Tax Expense | -78.00K | 96.00K | 117.00K | 124.00K | 132.00K | 1.00K | 2.00K | -470.00K | -6.17M | -4.33M | 24.00K |
| Net Income | -28.12M | -64.89M | -61.68M | -46.61M | -56.75M | -36.89M | -43.64M | -39.10M | -20.83M | -12.13M | -3.25M |
| Net Income Ratio | -431.67% | -1,607.41% | -4,555.39% | 0.00% | -2,935.64% | -746.69% | 2,853.96% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| EPS | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EPS Diluted | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| Weighted Avg Shares Out | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
| Weighted Avg Shares Out (Dil) | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key...
ProQR Announces Year End 2023 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial...
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates...
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced a collaboration...
Is ProQR (PRQR) Stock a Solid Choice Right Now?
ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
ProQR Announces Third Quarter 2023 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today reported its financial...
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strengthened its leading intellectual property (IP) estate with...
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Daniel...
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company...
Source: https://incomestatements.info
Category: Stock Reports